These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31795121)

  • 1. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
    Van den Bossche J; Domen A; Peeters M; Deben C; De Pauw I; Jacobs J; De Bruycker S; Specenier P; Pauwels P; Vermorken JB; Lardon F; Wouters A
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
    Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
    World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
    Li L; Xue W; Shen Z; Liu J; Hu M; Cheng Z; Wang Y; Chen Y; Chang H; Liu Y; Liu B; Zhao J
    Mol Ther Oncolytics; 2020 Sep; 18():215-225. PubMed ID: 32728610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
    Hong M; Ren M; Silva J; Kennedy T; Choi J; Cowell JK; Hao Z
    Am J Cancer Res; 2014; 4(2):135-47. PubMed ID: 24660103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
    Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
    Dong J; Park SY; Nguyen N; Ezhilarasan R; Martinez-Ledesma E; Wu S; Henry V; Piao Y; Tiao N; Brunell D; Stephan C; Verhaak R; Sulman E; Balasubramaniyan V; de Groot JF
    Oncotarget; 2018 Feb; 9(12):10497-10509. PubMed ID: 29535822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma.
    Pandey A; Tripathi SC; Mai J; Hanash SM; Shen H; Mitra S; Rostomily RC
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
    Mancini M; Monaldi C; De Santis S; Rondoni M; Papayannidis C; Sartor C; Curti A; Bruno S; Cavo M; Soverini S
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volasertib suppresses the growth of human hepatocellular carcinoma
    Zheng DW; Xue YQ; Li Y; Di JM; Qiu JG; Zhang WJ; Jiang QW; Yang Y; Chen Y; Wei MN; Huang JR; Wang K; Wei X; Shi Z
    Am J Cancer Res; 2016; 6(11):2476-2488. PubMed ID: 27904765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
    Xin X; Lin F; Wang Q; Yin L; Mahato RI
    ACS Appl Mater Interfaces; 2019 Apr; 11(16):14647-14659. PubMed ID: 30933478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.
    Xie FF; Pan SS; Ou RY; Zheng ZZ; Huang XX; Jian MT; Qiu JG; Zhang WJ; Jiang QW; Yang Y; Li WF; Shi Z; Yan XJ
    Am J Cancer Res; 2015; 5(12):3548-59. PubMed ID: 26885445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.